Company / Return on Equity (ROE)
aTYR PHARMA INC Return on Equity (ROE) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-109.8%
FY2025
5-year range
-109.8% / -21.6%
FY2021-FY2025
Trend
-20.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
aTYR PHARMA INC reports negative total equity of -109.8% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-109.8% in FY2025 with a 5-year CAGR of -0.8%.
Declined from -37.3% to -109.8% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -87.1pp
- 5-Year Change
- -0.8pp
- 10-Year Change
- -
Key checks
Key Insights
- aTYR PHARMA INC's return on equity (roe) has declined for 4 consecutive years.
- In FY2025, return on equity (roe) decreased 20.1% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -109.8% | -20.1% |
| FY2024 | -91.4% | -145.5% |
| FY2023 | -37.3% | -64.1% |
| FY2022 | -22.7% | -5.1% |
| FY2021 | -21.6% | +80.2% |
| FY2020 | -109.0% | -45.3% |
| FY2019 | -75.0% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026